Population Control and Contraception: A Hamburg Family Affair
The FDA, under the direction of Dr. Margaret Hamburg, has now approved over-the-counter sales of Plan B One-Step emergency contraception to people 15 years of age and older. Just two years ago, the legal age was 17 and older.
Originally, the pharmaceutical manufacturer Teva applied to the FDA to have the contraceptive be available to anyone of any age, but even abortion fanatic Kathleen Sebelius, head of the HHS, knew that easy access to contraceptives by very young girls would be reckless and could bring in an avalanche of lawsuits. So she blocked the FDA from approving that application.
But the real story behind all of this maneuvering over when a teenager understands the implications and complications of taking a morning-after pill goes back to who's in charge at the FDA.
Population-control eugenicists raised Dr. Hamburg.
Dr. Hamburg, daughter of psychiatrists -- one of whom served as president of the leftist Institute of Medicine (David Hamburg, director IOM 1975-1980), and both of whom served as directors of the American Eugenics Society (David Hamburg, 1989-1991; Beatrix Hamburg, 1983) -- has carried on in the tradition of her parents. She was inducted into the IOM in 1994, at which time she remarked "There was a sense of real fun that the father-mother-daughter constellation had been formed."
This family fits the definition of eugenics -- selective breeding through reproducing "superior" stock. Her mother's specialty was in teenage mental health and pregnancy prevention, while her father specialized in human genetics research. Emergency contraceptives play an integral part in eugenicists' dreams of weeding out inferior and undesirable people from the planet.
In 1979, David Hamburg wrote "Disease Prevention: The Challenge of the Future," in which he addresses the future of contraception.
The general orientation of the WHO effort in this field is to make possible an array of contraceptive techniques and relate these to cultural preferences with respect to acceptability. Two new approaches are of great interest: I) work on brain peptides...2) applications of a prostaglandin ... A practical approach to pregnancy interruptions merging through prostaglandin use in the three weeks following a missed menstrual period. In this interval, the interruption is practically always complete. Current research may lead to a simple, effective technique for self administration.
David and Beatrix passed the torch to Margaret, who now has a Muckety score of 99! "Muckety scores use connections to measure influence. If someone has a score of 99, it means that he or she has more connections and influence than 99 percent of the others in our listings of the most influential people in America ... which focuses primarily on U.S. business, government, politics and entertainment."
Margaret's husband Peter Fitzhugh Brown is the co-chief executive officer, co-president, and director at Renaissance Technologies Corp., the world's largest hedge fund manager. When Hamburg was first nominated in 2009 for the FDA post, critics pointed out the conflict of interest her husband's company would have with her new job. No worries.
Conflicts of interest in the Obama administration mean nothing. If you are of Obama's ilk, you're in. Congress? What's that?
And back in 2011, when the FDA was set to approve Teva's application for 11-year-olds to buy Plan B One-Step, Margaret Hamburg was in charge. In 2012, three years after Hamburg took the helm, another drug, Wellbutrin XL, "manufactured by Impax Laboratories and marketed by Teva Pharmaceuticals[,] was being recalled because it did not work[.]" This further called into question Hamburg's irresponsible attitude towards drug regulation.
From Forbes in October 2012:
The FDA announced last week that the 300mg generic version of Wellbutrin XL And this wasn't just a problem with one batch - this is a problem that has been going on with this particular drug for four or five years, and the FDA did everything it could to ignore it. [snip]
Instead of doing its own study on the drug, the FDA asked the drug maker to conduct a study to determine whether the generic drug was equivalent to the brand. The FDA, in their recent press release, claims that Teva started the trial but later abandoned it because of slow patient enrollment. It was already 2010, several years after knowing there was a problem, the FDA was forced to do its own study. [snip]
The FDA Commissioner Peggy Hamburg needs to answer for this. When you keep score by loved ones' worry and by patient lives cut short by suicide, this is not just the tale of a simple recall, but of a failure of the system and sign of dangerous incompetence.
Sure, the Wellbutrin scandal started before Hamburg came on board, but why did it take her three years to rectify the blatant blunder? Then again, people who think they can run the world by choosing who lives and who dies wouldn't even register that 11-year-olds can't make adult decisions, and depressed patients can't wait three years for their meds to be fixed.
How much influence should someone with the mindset of a eugenicist and a questionable history with the FDA have?
Read more Ann Kane at Potter Williams Report.